KRMD$3.78
$4.11
Chart
Performance
Key Stats
AI KRMD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldKORU Medical Systems shows mixed signals. While its core business is sound and has niche growth potential, it faces profitability challenges and uninspiring technicals. Diversification and cautious optimism are advised.
Thematic
KORU Medical Systems operates in the growing market of subcutaneous drug delivery, which is supported by trends towards patient convenience and home-based therapies. However, it lacks exposure to broader, high-growth tech themes.
Fundamental
KORU Medical Systems demonstrates solid revenue growth and a healthy balance sheet with manageable debt. However, persistent net losses and negative EPS are significant concerns.
Technical
KORU Medical Systems exhibits mixed technical indicators. While some short-term moving averages offer a 'Buy' signal, longer-term indicators and key oscillators suggest caution or potential overhead resistance.
| Factor | Score |
|---|---|
| Medical Device Innovation | 75 |
| Healthcare Sector Growth | 70 |
| Patient-Centric Care Trends | 80 |
| Technological Integration (AI/Digital Health) | 30 |
| Regulatory Landscape (Medical Devices) | 60 |
| Factor | Score |
|---|---|
| Valuation | 45 |
| Profitability | 20 |
| Growth | 70 |
| Balance Sheet Health | 80 |
| Cash Flow | 35 |
| Earnings Per Share (EPS) | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Volume Confirmation | 55 |
| Support & Resistance | 65 |
| Short-Term Oscillators | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive EPS Surprises
The company has consistently exceeded earnings per share (EPS) estimates in recent quarters. For example, in Q2 2025, the reported EPS of -0.02 beat the estimate of -0.03 by 28.57%.
Increasing Revenue Trend
Revenue has shown a generally upward trend, increasing from $23.49 million in Q4 2021 to $33.65 million in Q4 2024.
Bearish Points (7)
Consistent Net Losses
The company has reported net losses for the past several years and quarters (e.g., Net Income of -$6.07 million in 2024), indicating ongoing profitability challenges.
Negative P/E Ratio
The trailing Price-to-Earnings (P/E) ratio is not applicable or negative due to consistent net losses, making traditional P/E valuation metrics unreliable and suggesting a speculative investment.
Calendar
August 2025
7
Next Earnings Date
H: $-0.01
A: $-0.02
L: $-0.03
H: 9.59M
A: 9.46M
L: 9.30M
Profile
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 and FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.
Seasonals
Price Target
5.50 USD
The 39 analysts offering 1 year price forecasts for KRMD have a max estimate of 7.00 and a min estimate of 3.50.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor and leading provider of infusion systems and solutions, having acquired Smiths Medical's infusion systems. Significant overlap in market and technology with KRMD.
Weight: 90
Major medical technology company with a broad portfolio including infusion pumps, medication management systems, and drug delivery devices. A key competitor and market influence for KRMD.
Weight: 88
Leading global provider of kidney care and hospital products, including IV solutions, infusion systems, and devices for home healthcare, aligning closely with KRMD's focus.
Weight: 85
Innovator in tubeless insulin patch pump technology (Omnipod), demonstrating advanced subcutaneous drug delivery capabilities, which is a core area of KRMD's expertise.